Antigen binding molecules targeting SARS-CoV-2

Inventors

GRIGORYAN, Gevorg • Ingraham, John

Assignees

Flagship Pioneering Inc • Flagship Pioneering Innovations VI Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11987616-B2

Patent

Publication Date

2024-05-21

Expiration Date


Abstract

The invention provides, in various embodiments, polypeptides (e.g., camelid antibodies and antigen binding fragments thereof) that specifically bind to Spike glycoprotein of severe acute respiratory syndrome coronavirus (e.g., SARS-CoV-2-Spike). The invention also provides, in various embodiments, fusion proteins comprising one or more of the polypeptides, polynucleotides encoding the polypeptides, vectors and host cells suitable for expressing the polypeptides, and methods for treating viral infections (e.g., COVID-19).

Core Innovation

The invention relates to antigen-binding polypeptides comprising an immunoglobulin heavy chain variable domain (V_H) that specifically binds a severe acute respiratory syndrome coronavirus 2 Spike glycoprotein (SARS-CoV-2-Spike). The binding is defined by heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3) that are identical to the HCDR1, HCDR2, and HCDR3 of an amino acid sequence of SEQ ID NO: 4. The disclosed molecules are camelid antibody/single-domain fragments configured around these V_H paratopes/CDRs.

The polypeptides are characterized by functional properties against SARS-CoV-2, including binding to Spike and/or RBD, including Spike variants. The disclosure further includes competition or blocking of ACE2 interaction, and reduction of SARS-CoV-2 Spike binding to ACE2 and/or TMPRSS2. These functional properties are linked to neutralization/infectivity inhibition in human cells, together with binding affinity ranges and assay readouts such as K_D and IC50/IC80.

In addition to the antigen-binding polypeptides themselves, the disclosure provides fusion proteins, polynucleotides, vectors, host cells, and pharmaceutical compositions, as well as therapeutic and prophylactic methods. Example data are described for binding and functional inhibition, including ELISA binding, ACE2 competition, yeast display affinity/kinetics, and pseudovirus neutralization, including resistance to emerging mutations.

Claims Coverage

The document provides two independent claims. The coverage is based on two main inventive feature sets: (i) a SARS-CoV-2-Spike-binding V_H defined by HCDR1/HCDR2/HCDR3 identical to SEQ ID NO: 4, and (ii) a SARS-CoV-2-Spike-binding polypeptide comprising a V_H having the amino-acid sequence of SEQ ID NO: 4.

HCDR-defined V_H for SARS-CoV-2-Spike binding

A polypeptide that specifically binds a SARS-CoV-2 Spike glycoprotein, comprising an immunoglobulin heavy chain variable domain (V_H) whose HCDR1, HCDR2, and HCDR3 are identical to the HCDR1, HCDR2, and HCDR3, respectively, of the amino acid sequence of SEQ ID NO: 4.

SEQ ID NO: 4 V_H for SARS-CoV-2-Spike binding

A polypeptide that specifically binds a SARS-CoV-2 Spike glycoprotein, comprising an immunoglobulin heavy chain variable domain (V_H) comprising the amino acid sequence of SEQ ID NO: 4.

Overall, the claim coverage centers on SARS-CoV-2-Spike-binding immunoglobulin V_Hs, with one independent claim defined by identity of HCDRs to SEQ ID NO: 4 and the other independent claim defined by the full amino-acid sequence of SEQ ID NO: 4.

Stated Advantages

Provides polypeptides that specifically bind SARS-CoV-2 Spike and/or RBD, including variants.

Competes with and blocks ACE2 interaction with SARS-CoV-2.

Reduces SARS-CoV-2 Spike binding to ACE2 and/or reduces SARS-CoV-2 infectivity in human cells.

Demonstrates neutralization/infectivity inhibition in human cells with stated K_D and IC50/IC80 ranges.

Includes resistance to emerging mutations, as described for the disclosed examples.

Documented Applications

Therapeutic and prophylactic methods are disclosed in connection with the antigen-binding polypeptides.

Pharmaceutical compositions are disclosed that include the disclosed polypeptides.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.